Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.77 |
| ▸ | TFEB | P19484 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | BCHE | P06276 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coumarinic Acid Methyl Ether SCHEMBL29369917 | 1.00 | NFE2L2 (0.77) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL83064 | 1.00 | NFE2L2 (0.77) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL79060 | 1.00 | NFE2L2 (0.77) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL4743620 | 0.98 | NFE2L2 (0.74) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL10437229 | 0.98 | NFE2L2 (0.74) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL8351832 | 0.98 | NFE2L2 (0.74) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL28250887 | 0.95 | NFE2L2 (0.71) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL22092089 | 0.93 | KDM4E (0.68) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL2468602 | 0.93 | NFE2L2 (0.68) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL28320175 | 0.93 | NFE2L2 (0.68) | NFE2L2TFEBKDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-6916890-B1 | Thermally reworkable epoxy resins and compositions based thereon | HENKEL CORPORATION (US) | 2005-07-12 | — | — | US | claimed |
| WO-2003031492-A1 | THERMALLY REWORKABLE EPOXY RESINS AND COMPOSITIONS BASED THEREO N | HENKEL CORPORATION (US) | 2003-04-17 | — | — | WO | claimed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. | 2023-02-09 | — | — | US | disclosed |
| EP-4073242-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | Kumquat Biosciences Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-6231880-B1 | ANTIGROWTH AGENTS FOR CELLS BY STIMULATING TO PATIENTS AND EFFECTIVE DIMETHYL SUBSTITUTED CARBOXYLIC ACID | Perrine, Susan P. | 2001-05-15 | — | — | US | disclosed |
| WO-2000007993-A1 | SUBSTITUTED ISOQUINOLEINES AND THEIR USE AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-02-17 | — | — | WO | disclosed |
| EP-0351856-B1 | Thiazolo[5,4-b]azepine compounds | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-09-15 | — | — | EP | disclosed |
| US-5300639-A | 2-oxo-3-carbonylamino-substituted azepine intermediates; lipoperoxide formation inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-05 | — | — | US | disclosed |
| US-5118806-A | Enzyme inhibitor for lipoxygenase; useful for treating cancer, hepatic diseases, inflammation, cerebrovascular diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-06-02 | — | — | US | disclosed |
| US-4956360-A | LIPOPEROXIDE INHIBITORS, ENZYME INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | NFE2L2 4821/4885TFEB 2171/4885KDM4E 2134/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | NFE2L2 2691/4885TFEB 2861/4885KDM4E 2917/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | NFE2L2 4821/4885TFEB 2171/4885KDM4E 2134/4885 |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | NFATC1, MYD88, ICOS | NFE2L2 1313/4885TFEB 2742/4885KDM4E 3453/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | NFE2L2 4821/4885TFEB 2171/4885KDM4E 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.